Study A0221049, which was a 12-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial was designed to compare the efficacy and safety of a flexible dose regimen of fesoterodine to placebo.
The trial met its primary endpoint which was evident by the superiority of Toviaz in reducing the mean number of urgency urinary incontinence (UUI) episodes per day, as compared to placebo.
Pfizer Global Primary Care Business Unit Medicines Development Group senior vice president and head Steven J Romano said the study was the first one of to test an antimuscarinic agent to demonstrate efficacy and safety in medically vulnerable seniors with overactive bladder.